Abstract
Although low-dose glucocorticoids, in conjunction with DMARDs, are known to halt or severely retard the erosive destruction of joints in patients with early rheumatoid arthritis (RA), the potential adverse effects of low-dose glucocorticoids and the benefit:risk ratio of treatment are a concern for many clinicians. Malysheva and colleagues undertook a retrospective, open-label review of the incidence and severity of adverse effects associated with DMARD treatment with or without glucocorticoids in patients with RA. Their results suggest that low-dose glucocorticoids actually help to postpone the occurrence of adverse effects caused by most standard DMARDs, which, if translated into a delay before biologic agents were required, would provide a substantial cost saving. Unfortunately, an increased incidence of adverse reactions was noted for glucocorticoid-treated patients compared with those patients on monotherapy; however, the undesirable effects were mostly mild in nature. This study sheds new light on the relative risks and benefits of low-dose glucocorticoid therapy in RA and adds further weight to the arguments for its appropriate use in early disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kirwan JR et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006356. 10.1002/14651858.CD006356
Luqmani R et al. (2006) British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). Rheumatology 45: 1167–1169
Da Silva JAP et al. (2006) Low-dose glucocorticoid therapy in rheumatoid arthritis: a review on safety: published evidence and prospective trial data. Ann Rheum Dis 65: 285–293
Malysheva OA et al. (2008) Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 35: 979–985
Capell HA et al. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63: 797–803
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Kirwan, J. Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship?. Nat Rev Rheumatol 4, 568–569 (2008). https://doi.org/10.1038/ncprheum0901
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0901